T3:PO.70
To report on the weight loss achieved in 8 weeks by 1810 female patients with BMI 25-29.9 on the LighterLife Lite LCD weight-loss programme in 2009; a retrospective study
Hallam CL, Mullins G, du Plessis J, Cox JSA and Hewlett B
LighterLife, Cavendish House, Harlow Business Park, Parkway, Harlow, Essex, UK

Introduction: LighterLife Lite is a commercial weight-management programme for patients with BMI 25–29.9. Weight loss is achieved with a low-calorie diet (LCD), comprising fortified, formula-food replacements and a calorie/carbohydrate-restricted meal, providing a daily intake of 801–1200 kcal, alongside behavioural modification specifically designed for weight management using transactional analysis and cognitive behavioural therapy techniques (TCBCT). Following weight loss, there is an ongoing weight-maintenance programme to implement and sustain healthy lifestyle changes, and thus reduce the risk of co-morbidities.

Aim: To determine mean weight loss and BMI reduction for female patients following 8 weeks on the LighterLife Lite weight-loss programme in 2009.

Method: Following screening for suitability, patients started LCD and were weighed weekly by their LighterLife weight-management counsellors. Data was available for 1810 women with BMI 25–29.9 who participated in the LighterLife Lite LCD for 8 weeks from February-August 2009.

Results: After 8 weeks on the LighterLife Lite LCD, mean weight loss was 7.1 kg (1st 2lb), mean BMI reduction was 2.7 and mean percentage weight loss 9.4%.

Mean start weight
Mean start BMI
Mean weight loss at 8 weeks
Mean % weight loss
Mean end BMI
Mean BMI reduction

Conclusion: Patients completing 8 weeks on the LighterLife Lite LCD programme achieved a mean loss of 7.1kg (1st 2lb; average 2lb per week), which is a mean BMI reduction of 2.7 and a reduction of 9.4% of body weight. This may improve health outcomes by reducing the risk of weight-related co-morbidities.

T3:PO.71
To report on the weight loss achieved in 8 weeks by 950 obese male patients on the LighterLife Total for Men VLCD weight-loss programme in 2009; a retrospective study
Hallam CL, Mullins G, du Plessis J, Cox JSA and Hewlett B
LighterLife, Cavendish House, Harlow Business Park, Parkway, Harlow, Essex, UK

Introduction: LighterLife Total for Men is a commercial weight-management programme specifically designed for men using transactional analysis and cognitive behavioural therapy techniques (TCBCT). Following weight loss, there is an ongoing weight-maintenance programme to help patients implement and sustain healthy lifestyle changes, and thus reduce the risk of co-morbidities.

Aim: To determine mean weight loss and BMI reduction for male patients following 8 weeks on the LighterLife Total for Men VLCD in 2009.

Method: Following screening suitability, patients started VLCD and were weighed and had ketone levels checked weekly by their Lighter-Life weight-management counsellors. This study reports on 950 men with BMI≥30 who completed 8 weeks on the LighterLife Total for Men VLCD programme from January-September 2009.

Results: A mean weight loss of 19.5 kg (3st 1lb) following 8 weeks on the LighterLife Total for Men VLCD and a mean BMI reduction of 6.1 were observed in male patients.

Mean start weight
Mean start BMI
Mean weight loss at 8 weeks
Mean % weight loss
Mean BMI reduction

Conclusion: Obese men completing 8 weeks on the LighterLife Total for Men VLCD achieved a mean loss of 19.5 kg (3st 1lb), which is a mean BMI reduction of 6.1 and in excess of 15% of their body weight. This may improve health outcomes by reducing the risk of weight-related co-morbidities.

T3:PO.72
Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format
Milsom V1, Malcolm R1, Cronan G1, Pechon S1, Miller-Kovach K2, Rost S2, O’Neill PM1
1Weight Management Center, Medical University of South Carolina, Charleston, SC, USA; 2Weight Watchers International, New York, NY, USA

Introduction: Average loss of 5–10% of body weight often improves cardiovascular risk factors. This is usually shown after 6–12 months of exposure to weight loss medications and/or intensive dietary, behavioral and/or exercise instruction. We assessed changes in risk factors after 12 weeks in a weight loss trial featuring a commercial format with limited dietary and exercise instruction.

Methods: Subjects (132 adults; BMI = 27–35) were randomized to 1 of 2 methods of counting food intake with weekly group meetings using a commercial weight loss program. Lipids, blood glucose, blood pressure and waist circumference were assessed at baseline and Week 12.

Results: One hundred and twelve subjects (100F,12M) completed final assessments. With no weight loss differences between conditions, analyses used the combined sample. M weight loss was 3.74 kg (SD = 3.16) and 4.37% of baseline weight (SD = 3.71). Significant improvements (P < .05) were seen on triglycerides, total cholesterol and LDL cholesterol. There were trends (P < .10) toward reductions in fasting glucose, systolic blood pressure, and HDL cholesterol. Among subjects with baseline values of the risk factor beyond recommended cut points, significant (P < .05) reductions were seen on triglycerides (n = 22), total cholesterol (n = 41), LDL cholesterol (n = 77), glucose (n = 8), systolic and diastolic blood pressure (n = 14), and waist circumference (n = 88), and a trend (P < .10) toward an increase in HDL (n = 57).

Conclusion: With modest weight loss over 12 weeks using a commercial format with limited diet instruction, improvements were seen in a number of risk factors, particularly among subjects with initially higher-risk values. The duration of these effects remains to be determined.

Conflict of interest: Research support (RM, GC, SP, PO) and employment (KK, SR) by Weight Watchers International.

Funding: This study was supported by a grant from Weight Watchers International.